Organization | St. Vincent Medical Center - Los Angeles

St. Vincent Medical Center - Los Angeles Report issue

Academic/Hospital Phase 2

Founded: Los Angeles CA United States (1856)

Organization Overview

First Clinical Trial

1987

NCT00002465

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

1996

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 2 Trials (7)

allogeneic tumor cell vaccine (2 trials)

cyclophosphamide (cytoxan) (3 trials)

interferon alpha-2b (Intron-A) (2 trials)

interferon gamma-1b (actimmune) (1 trial)

megestrol (megace) (1 trial)

muromonab cd3 (Orthoclone OKT3) (1 trial)

sargramostim (leukine) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 2)

Endometrial Neoplasms (Phase 2)

Kidney Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Mesothelioma (Phase 2)

Pancreatic Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 4
# of Trial APIs: 7